ArriVent BioPharma, Inc. Common Stock (AVBP)
Automate Your Wheel Strategy on AVBP
With Tiblio's Option Bot, you can configure your own wheel strategy including AVBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVBP
- Rev/Share 0.0
- Book/Share 7.1379
- PB 2.6878
- Debt/Equity 0.0004
- CurrentRatio 12.7393
- ROIC -0.5934
- MktCap 778315171.0
- FreeCF/Share -3.6173
- PFCF -6.1464
- PE -4.9027
- Debt/Assets 0.0004
- DivYield 0
- ROE -0.5548
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AVBP | Goldman | -- | Buy | -- | $33 | July 10, 2025 |
| Initiation | AVBP | B. Riley Securities | -- | Buy | -- | $37 | March 20, 2025 |
| Initiation | AVBP | Guggenheim | -- | Buy | -- | $45 | March 10, 2025 |
News
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent Company progress.
Read More
ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be in early 2026.
Read More
New Strong Sell Stocks for July 21st
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
CDZI, AVBP and ACCO have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2025.
Read More
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients
Read More
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET.
Read More
ArriVent BioPharma Reports First Quarter 2025 Financial Results
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first …
Read More
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D.
Read More
About ArriVent BioPharma, Inc. Common Stock (AVBP)
- IPO Date 2024-01-26
- Website https://www.arrivent.com
- Industry Biotechnology
- CEO Zhengbin Yao
- Employees 52